Cover Page To Our Shareholders Issues and Answers: Contributions That Count Enterprise Profile Financials Summary Financial Review Report of Management Report of Ernst & Young LLP, Independent Auditors Financial Statements Notes to Consolidated Financial Statements Corporate Information Board of Directors and Officers

BD mobilizes to support worldwide effort to anticipate and respond to bioterrorist threats Thirty years after routine inoculations for smallpox ended in the U.S., bioterrorism has introduced a new and unnerving dimension to life. In the fall of 2001, inhalational anthrax claimed a man’s life in Florida and everyday letters were transformed into deadly weapons.     As these events unfolded, BD mobilized to support mass immunization campaigns and emergency response to bioterrorist incidents. In this environment, smallpox infection, once virtually eradicated, arose as a threat. In response, BD quickly began to produce the BD Bifurcated Needle, basing it on a proven design recommended by the World Health Organization. In addition, a number of advanced drug delivery devices, under development at BD Technologies, appear to increase the efficacy of vaccine delivery and are being studied for their potential in biodefense applications. To that end, BD has a cooperative research and development agreement with the U.S. Department of Defense to develop advanced vaccine delivery systems for biodefense.     In an important agreement with the State of New Jersey, the Company is conducting a pilot test of the BD Bio-Terror Preparedness Network, an information technology-based solution developed for tracking smallpox vaccinations.     Products from BD have already been called on for biodefense, specifically the BD BACTEC System, which was used to confirm the initial case of inhalational anthrax, and special monitoring plates from BD Diagnostic Systems, which identified the presence of environmental anthrax. On the research front, flow cytometers and reagents from BD Biosciences are being used to study the effect of bioterror agents on the immune system. THE ISSUE “New Jersey was the epicenter of the anthrax bioterrorism of last year. The events were a wake-up call for our state and the nation. New Jersey responded by developing a robust plan for preparedness and response to the health-related threats of terrorism.” - Clifton R. Lacy, M.D. Commissioner, Department of Health and Senior Services, State of New Jersey OUR EXPERTISE Shortly after terrorism erupted in the United States, BD emerged as a company with capabilities essential for assisting the nation–and countries around the world–with biodefense preparedness and response. BD is positioned to support biodefense needs because of capabilities found in all three of its worldwide business segments, principally expertise and supplies for mass vaccinations, but also clinical analysis for rapidly categorizing organisms and research tools for studying the effects of pathogens on the immune system. OUR CONTRIBUTION BD is committed to serving the public interest by helping governments around the world respond to threats posed by life-threatening bioterror agents. For smallpox vaccinations, for example, the Company is shipping worldwide orders for its FDA-cleared and European CE-marked BD Bifurcated Needle. The tiny two-pronged needle holds a droplet of the vaccine containing the proper dose, which is delivered through a series of punctures to the skin.